# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-130938
Filing Date
2022-04-29
Accepted
2022-04-29 09:15:32
Documents
8
Period of Report
2022-06-22

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d291624ddef14a.htm | DEF 14A | 589162
2 | GRAPHIC | g291624g01d13.jpg | GRAPHIC | 25403
3 | GRAPHIC | g291624g16n01.jpg | GRAPHIC | 185258
4 | GRAPHIC | g291624g39u12.jpg | GRAPHIC | 30489
5 | GRAPHIC | g291624g70d01.jpg | GRAPHIC | 201531
6 | GRAPHIC | g291624g70d02.jpg | GRAPHIC | 172489
7 | GRAPHIC | g291624g80a43.jpg | GRAPHIC | 50977
8 | GRAPHIC | g291624g91b29.jpg | GRAPHIC | 48664
| Complete submission text file | 0001193125-22-130938.txt |  | 1559043

Mailing Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39567 | Film No.: 22870738
SIC: 2836 Biological Products, (No Diagnostic Substances)